Initial therapy before surgery for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial looks at how well certain initial treatments (like targeted therapy, immunotherapy, or liver-directed procedures) work in people with liver cancer who have not had surgery yet. It aims to see if these treatments can shrink the tumor enough to allow removal later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hepatocellular carcinoma (HCC), a type of liver cancer.
- Your first treatment was one of these: chemotherapy through a liver artery (HAIC), blocking blood supply to the tumor (TACE), targeted pills (TKIs), immunotherapy (ICIs), or radiation therapy.
- You are able to carry out normal daily activities or only limited in strenuous activity (ECOG score 0 or 1).
- Your liver function is relatively good (Child-Pugh score 5 to 7, meaning mild to moderate liver damage).
- You have not had any other cancer in the last 5 years.
- You have complete medical records and have been followed for at least 3 months after treatment started.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy, immunotherapy, and targeted drugs before surgery helps prevent liver cancer from coming back in patients with high-risk tumors. You would receive treatment to shrink the tumor before your scheduled surgery.
This trial tests a combination of treatments for liver cancer that can be surgically removed. It adds immunotherapy drugs (Iparomlimab and Tuvonralimab, together called QL1706) and targeted therapy (Lenvatinib) to a procedure called TACE (chemoembolization) to see if this approach shrinks the tumor and lowers the chance of recurrence after surgery.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
This trial tests a combination of liver procedures (TACE or HAIC) with anti-angiogenic drugs and immunotherapy to shrink liver cancer that cannot be removed with surgery. If the tumor shrinks enough, you may be able to have surgery or continue with other treatments.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.